Supplementary Figure S5 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination

Addition of OP-1250 to CDK4/6 inhibitors enhances tumor suppression and prolongs animal survival in ER+ breast cancer xenograft models. A, B, Percent change in tumor volume of individual animals in listed treatment groups at day 29 of the MCF7 xenograft study, normalized to day 1 tumor volume. C, D, Percent change in tumor volume of individual animals in listed treatment groups at day 29 of the ST941 xenograft study, normalized to day 1 tumor volume. E, F, Kaplan–Meier graphs of animal survival over time in listed treatment groups of mice implanted with the ESR1Y537S ST941 PDX model. Dosing ended on day 29 of the study, and animals were sacrificed when tumor volume reached 2000 mm3. G, H, Mean and SEM tumor volume over the full study interval with monotherapy and combination treatments in the ESR1Y537S ST941 PDX breast cancer model, with the dotted line representing tumor stasis. Dosing ended on day 29, as indicated by the dashed line.